Dogwood prices 578,950 shares at $8.26 in registered direct offering

Dogwood (DWTX) Therapeutics entered into a securities purchase agreement with certain institutional investors to purchase 578,950 shares of common stock at an offering price of $8.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds for the offering are expected to be approximately $4.8M before deducting placement agent fees and other offering expenses. This offering is expected to close on March 14, 2025, subject to customary closing conditions. Dogwood intends to use the net proceeds of this offering to further advance the clinical development of its lead development candidate, Halneuron, and for working capital and general corporate purposes. Maxim Group is acting as sole placement agent in connection with the offering.